Active Biotech (STO:ACTI), a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer, announced on Tuesday that its partner, NeoTX Therapeutics Ltd (NeoTX), will present new preclinical data on the drug candidate naptumomab estafenatox (naptumomab, ANYARA) at the scientific conference at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting being held from 6 November 2019 t0 10 November at National Harbour, Maryland, US.
This poster presentation will highlight preclinical data demonstrating that naptumomab and checkpoint inhibitors work synergistically to induce a prolonged and protective immune response against solid tumours.
Titled 'Selective T cell Redirection Proteins (STR) Enhance the Anti-Tumor Activity of Checkpoint Inhibitors (CPIs) and can Lead to Long-Lasting Immunity Against the Tumor', the presentation will be made by Meir Azulay PhD on 8 November 2019 from 12:30 to 14:00 hours CET.
In connection with the presentation, the poster will be available on https://www.activebiotech.com.
Naptumomab was licensed from Active Biotech to NeoTX in 2016. NeoTX is responsible for the global development and commercialization of naptumomab for the treatment of cancer under the license agreement.
NeoTX is a clinical-stage biopharmaceutical company dedicated to developing promising therapeutic candidates in the field of immuno-oncology.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval